The TRAIL to arthritis
George C. Tsokos, Maria Tsokos
George C. Tsokos, Maria Tsokos
Published November 1, 2003
Citation Information: J Clin Invest. 2003;112(9):1315-1317. https://doi.org/10.1172/JCI20297.
View: Text | PDF
Commentary

The TRAIL to arthritis

Abstract

Antigen-specific lymphocytes are involved in synovial proliferation within inflamed joints. Activated lymphocytes and synoviocytes from patients with rheumatoid arthritis express receptors that can bind TNF-related apoptosis-inducing ligand (TRAIL). A new study demonstrates that DCs pulsed with collagen and transduced with an adenovirus-based vector able to express TRAIL limit the incidence of arthritis in a model of collagen-induced arthritis and joint inflammation. These results suggest that gene-modified cell therapy represents a therapeutic option for systemic rheumatic diseases.

Authors

George C. Tsokos, Maria Tsokos

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Gene-modified cell therapy in arthritis. (a) DCs prepared from either th...
Gene-modified cell therapy in arthritis. (a) DCs prepared from either the peripheral blood or the bone marrow are pulsed with collagen type II (CII) and transfected with an adenovirus expressing TRAIL (AdTRAIL) to produce CII-DC-AdTRAIL-DOX. (b) Injection of CII into mice leads to a cascade of events that include lymphocyte activation, lymphokine production followed by synovial cell proliferation, and joint inflammation. (c) Infusion of DOX-inducible TRAIL-expressing DCs pulsed with CII suppresses collagen-induced arthritis (CIA) by eliminating CII-specific T cells.